

## Effect of Helicobacter Pylori Eradication on Hepatic Encephalopathy in Egyptian Cirrhotic Patients

EMAN MEDHAT, M.D.<sup>1</sup>; HANAN FOUAD, M.D.<sup>2,3</sup>; AHMED KHAIRY, M.D.<sup>1</sup>;  
MOHAMED Z. HAIDE, M.D.<sup>4</sup> and ZEINAB ZAKARIA, M.D.<sup>1</sup>

The Department of Endemic Medicine & Hepato-Gastroenterology, Faculty of Medicine, Cairo University<sup>1</sup>, Medical Biochemistry & Molecular Biology, Faculty of Medicine, Cairo University<sup>2</sup> and Galala University, Suez Governorate<sup>3</sup> and Hepatology & Gastroenterology Department at Ahmed Maher Teaching Hospital<sup>4</sup>

### Abstract

**Background:** Much ammonia is produced by helicobacter pylori and by its eradication, the grade of hepatic encephalopathy could be improved.

**Aim of Study:** To evaluate the effect of H. pylori eradication on the stage of hepatic encephalopathy.

**Patients and Methods:** This study included 80 cirrhotic patients infected with H. pylori which was diagnosed by stool antigen. The studied patients were further subdivided into groups according to the regimen of H. pylori eradication. Follow-up was done after one month to assess the effect of its eradication on the improvement of hepatic encephalopathy.

**Results:** Follow-up after one month of treatment revealed that the eradication rate for H. pylori showed higher efficacy with Levofloxacin based therapy (89.47%) compared to Clarythromycin regimen (76.47%) with *p*-value=0.3. Most of cirrhotic patients with hepatic encephalopathy improved after successful eradication however without a statistical significance.

**Conclusions:** Our results showed that H pylori eradication may improve the grade of hepatic encephalopathy.

**Key Words:** Liver cirrhosis – Hepatic encephalopathy – H. Pylori eradication.

### Introduction

**HELICOBACTER** pylori (H. pylori) infection is reaching over 70% in developing countries. This infection has been associated with various gastrointestinal diseases [1]. It was reported that H. pylori in Egyptian patients with cirrhosis was higher than those without cirrhosis [2].

Hepatic encephalopathy (HE) is a serious and frequent complication of liver cirrhosis; the pathophysiology of this complication is not completely understood. Among the leading precipitating factors

are increased blood ammonia levels [3]. Previous studies showed that after H.pylori eradication, grade of hepatic encephalopathy has improved [4].

The aim of this study was to evaluate the role of H. pylori eradication in the improvement of HE in cirrhotic patients.

### Patients and Methods

The present study included 80 cirrhotic patients based on clinical, laboratory and abdominal ultrasonographic findings. They infected with H pylori which diagnosed by stool antigen (BIONEXIA® H. pylori Ag, 415669, bioMérieux Asean, China). They were selected from hepatology department and outpatient clinic of Ahmed Maher Hospital, Cairo, Egypt. Over a period of one year from 2017 to 2018.

They were above 18 years old, they had hepatic encephalopathy grade I or II. The diagnosis of hepatic encephalopathy was based on clinical findings mostly in the form of tremors and slurred speech. The exclusion criteria were; the presence of active bleeding, active infection, hepatocellular carcinoma (HCC), renal impairment (Cr >2mg/dl), recent PPI and antacids, and other causes of encephalopathy such as: Encephalitis, hyperglycemia or hypoglycemia and acute fulminant hepatic failure, electrolyte imbalance. A written consent was obtained before enrollment in the study.

The encephalopathic patients were subdivided into 20 patients (HEA1) who received treatment to H. pylori (PPI in its standard dose combined with amoxicillin 1gm bid and clarithromycin 500 mg bid) for 10 days [5], and 20 patients (HEA2) received another treatment regimen to H. pylori

Correspondence to: Dr. Zeinab Zakaria,  
E-Mail: [zenab.zakaria@yahoo.com](mailto:zenab.zakaria@yahoo.com)

(standard dose of PPI, Amoxicillin 1gm bid and Levofloxacin 500mg once a day) for 10 days [6], while the remaining 40 patients (HEB) did not receive treatment for H. pylori.

For follow-up after eradication we also used H pylori stool antigen kit (BIONEXIA® H. pylori Ag, 415669, bioMérieux Asean, China), after one month from completing treatment regimen.

**Statistical analysis:**

Numerical data were expressed as mean and standard deviation. For quantitative variables, comparison between two groups was done using *t*-test, and for 3 groups or more ANOVA test was used. Qualitative data were expressed as frequency and percentage. *p*-value is considered to be significant if <0.05 and highly significant if <0.001.

**Results**

Among the studied patients, age ranged from 38 to 68 years, the mean age was 54.6 ±7.58 SD with female predominance (52%). Table (1).

Table (1): Demographic characteristics of the studied groups.

Gender	HEA1		HEA2		HEB		<i>p</i> value
	N	%	N	%	N	%	
Male	10	50.0	10	50.0	18	45.00	0.87
Female	10	50.0	10	50.0	22	55.0	
Total	20	100	20	100	40	100	
Age Range	45-68		43-66		38-67		
Mean ± SD	55.9±6.16		56.35±7.29		56.6±7.93		

Table (2) shows the Child score of the studied groups.

Table (2): Child score of the studied cirrhotic groups.

	Child score		Anova	
	Range	Mean ± SD	F	<i>p</i>
HEA1	11-14	12.75±0.91	24.99	0.07
HEA2	11-14	12.70±1.17		
HEB	10-14	12.30±0.97		

After one month of treatment, three patients from group HEA1, and one patient from group HEA2 were lost their follow-up. The eradication rate for H. pylori by per protocol (PP) analysis for HEA1 group was (76.47%) compared to (89.47%) for group HEA2. There was no significant difference between the two groups however the line of treatment with levofloxacin had higher efficacy. Table (3) & Fig. (1).

Table (3): The efficacy of treatment regimens.

Stool antigen	Group						<i>P</i> -value
	HEA1		HEA2		Total		
	N	%	N	%	N	%	
Negative (Eradicated)	13	76.47	17	89.47	30	83.33	0.296
Positive (not eradicated)	4	23.53	2	10.53	6	16.67	
Total	17	100.00	19	100.0	36	100.00	




Fig. (1): The efficacy of treatment regimens.

Follow-up data of the studied patients in relation to treatment response showed that the grading of encephalopathy before treatment among HEA1 was 80% grade I and 20% grade II. After eradication; 13 patients were eradicated (8 patients 61.54% recovered, 4 patients 30.77% were grade I and one patient 7.69% was grade II) while 4 patients were not eradicated and 3 patients were missed their follow-up (3/7 recovered; 42.8% and 1/7 was grade II; 14.4%).

Regarding HEA2 we found 75% were grade I and 25% were grade II. After eradication; 17 patients were eradicated (11 patients 64.71% recovered, 3 patients 17.65% were grade I and 3 patients 17.65% were grade II), while 2 patients were not eradicated and one patient missed the follow-up (one patient recovered 1/3; 33.3% and 1/3 was grade I; 33.3%).

As regards HE B of them 65% were grade I and 35% were grade II. On follow-up without eradication of H. pylori 21 patients recovered (52.5%), Eleven patients were grade I (27.5%) and 2 patients were grade II (5%) and 6 patients missed the follow-up. Table (4) & Fig. (2).

Table (4): Follow-up data of the studied patients in relation to treatment response.

	Group								P-value
	HEA1		HEA2		HEB		Total		
	N	%	N	%	N	%	N	%	
<b>Grading of HE:</b>									
Grade I	16	80.00	15	75.00	26	65.00	57	71.25	0.43
Grade II	4	20.00	5	25.00	14	35.00	23	28.75	
<b>Follow-up grading</b>									
<b>Eradicated:</b>									
Recovered	8	61.54	11	64.71	0	0.00	19	63.3	0.57
Grade I	4	30.77	3	17.65	0	0.00	7	23.3	
Grade II	1	7.69	3	17.65	0	0.00	4	13.3	
<b>Not eradicated:</b>									
Not follow-up	3	42.8	1	33.3	6	15.00	6	13.04	0.52
Recovered	3	42.8	1	33.3	21	52.50	25	54.35	
Grade I	0	0.00	1	33.3	11	27.50	12	26.09	
Grade II	1	14.4	0	0.00	2	5.00	3	6.52	




Fig. (2): Follow-up data of the studied patients in relation to treatment response.

**Discussion**

Previous studies on the association of H. pylori infection with HE and on the reduction of ammonia by H. pylori eradication have not been conclusive [7].

In the current study we aimed to investigate the impact of H. pylori eradication on the severity of hepatic encephalopathy.

Previous studies found that patients with H. pylori infection had significantly higher gastric juice ammonia concentrations than those without infection, however they stated that H. Pylori infection does not seem to play a major role in the pathogenesis of hyperammonemia in cirrhotic

patients [8,9]. There may be a relationship between H Pylori and HE in cirrhosis. Eradicating H Pylori may be beneficial for the clinical prevention and treatment of HE in liver cirrhosis [10]. On the other hand, a study was done by Miquel et al who found that the diffuse distribution of H pylori in the stomach contributes partly to hyper ammonia in patients with liver cirrhosis [11]. Others stated that ammonia production in stomach which does not increase blood level of ammonia in normal persons, can elevate the ammonia level in blood of cirrhotic patients because of reduction in ammonia metabolism [12].

In addition to Abdel Hady et al., who documented a significant increase in plasma endotoxin in

association with *H. pylori* infection in cirrhotic patients [13]. Which is cytotoxic on the endothelial cells of the blood-brain barrier in vitro.

Theoretically these differences may be due to the effect of child score or microbe density that generally has not been evaluated. In one study on cirrhotic patients by Zullo et al., inhibitory effect of urease activity on decrease of blood ammonia was seen only in patients with child-Pugh B/C and high density microbe [14].

The choice of the optimal regimen for *H. pylori* eradication is debated. The standard triple therapy (STT) using amoxicillin, clarithromycin and omeprazole, is one of the widely used regimens for *H. pylori* eradication. Levofloxacin based therapy (LBT) were used as rescue regimens in case of failure with standard regimen [15].

The results of the present study showed a higher eradication of *H. pylori* in patients who received Levofloxacin based therapy HE A2 (89.47%) when compared to those administered Standard triple therapy HEA1 (76.47%), but statistical analysis failed to show any significance in these differences ( $p$ -value=0.3). These results were in agreement with other studies [16,17].

In our study we performed grading of encephalopathy after one month of treatment of *H. pylori* and we found improvement of HE grade as among HEA1 we had 13 patients with *H. pylori* eradication of them 8 patients (61.54%) recovered, also in HEA2 we found 11 patients out of 17 recovered (64.71%) however did not show significant relation to eradication of *H. pylori* and that was in agreement with other studies [18,19]. In addition to the 40 cirrhotic patients who did not receive eradication 21 of them recovered (52.5%). Moreover the not eradicated patients showed recovery as in HEA1 and HEA2 (3/7; 42.8% & 1/3; 33.3%) respectively.

Similarly a study done by Agrawal et al., has concluded that there was improvement in psychometric tests and improved manifestations of MHE after *H. pylori* eradication. The absence of significant relation between eradication and HE grading may be due to the effect of child score as most of our patients were child C in comparison to child score of the other study which were A and B [19].

Concerning the 40 cirrhotic patients who did not receive treatment for *H. pylori*, they received the proper line of treatment after one month follow-up.

### Conclusions:

Our results showed that *H. pylori* eradication may improve the grading of hepatic encephalopathy.

### References

- 1- BRAVO D., HOARE A., SOTO C., VALENZUELA M.A. and QUEST A.F.: *Helicobacter pylori* in human health and disease: Mechanisms for local gastric and systemic effects. *World J. Gastroenterol.*, 24 (28): 3071-89, 2018.
- 2- EL-MASRY S., EL-SHAHAT M., BADRA G., ABOEL-NOUR M.F. and LOTFY M.: *Helicobacter pylori* and Hepatitis C Virus Coinfection in Egyptian Patients. *J. Glob. Infect Dis.*, 2 (1): 4-9, 2010.
- 3- CORDOBA J.: Hepatic Encephalopathy: From the Pathogenesis to the New Treatments. *ISRN Hepatol. Hindawi*, 1-16, 2014.
- 4- NANDAKUMAR R., NAIK A.S., PANDIT B., KAMAT R. and BHATIA S.J.: Effect of *Helicobacter pylori* eradication on serum ammonia levels in patients with chronic liver disease. *Indian J. Gastroenterol. Off J. Indian Soc. Gastroenterol.*, 22 (6): 221-3, 2003.
- 5- MALFERTHEINER P., MEGRAUD F., O'MORAIN C., BAZZOLI F., EL-OMAR E., GRAHAM D., HUNT R., ROKKAS T., VAKIL N. and KUIPERS E.J.: Current concepts in the management of *Helicobacter pylori* infection: The Maastricht III Consensus Report. *Gut*, 56 (6): 772-82, 2007.
- 6- GISBERT J.P. and PAJARES J.M.: *Helicobacter pylori* "rescue" therapy after failure of two eradication treatments. *Helicobacter*, 10 (5): 363-72, 2005.
- 7- SCHULZ C., SCHÜTTE K., REISENER N., VOSS J. and MALFERTHEINER P.: Prevalence of *Helicobacter pylori* Infection in Patients with Minimal Hepatic Encephalopathy. *J. Gastrointest Liver Dis. JGLD*, 25 (2): 191-5, 2016.
- 8- CHAKRABARTI P., ZULLO A., HASSAN C., PANDIT A., CHOWDHURY A., SANTRA A., HAZRA B., MORINI S. and ROY T.: *Helicobacter pylori*, gastric juice, and arterial ammonia levels in patients with cirrhosis. *J. Clin. Gastroenterol.*, 34 (5): 578-81, 2002.
- 9- ZULLO A., RIDOLA L., DE FRANCESCO V. and HASSAN C.: *Helicobacter pylori* Eradication for Hepatic Encephalopathy Treatment: The Ideal Study Is Still Lacking! *J. Clin. Gastroenterol.*, 49 (1): 88, 2015.
- 10- NANDAKUMAR R., NAIK A.S., PANDIT B., KAMAT R. and BHATIA S.J.: Effect of *Helicobacter pylori* eradication on serum ammonia levels in patients with chronic liver disease. *Indian J. Gastroenterol.*, 22 (6): 221-3, 2003.
- 11- MIQUEL J., BARCENA R., BOIXEDA D., FERNÁNDEZ J., SANROMAN A.L., MARTÍN-DE-ARGILA C. and RAMOSA F.: Role of *Helicobacter pylori* infection and its eradication in patients with subclinical hepatic encephalopathy. *Eur. J. Gastroenterol. Hepatol.*, 13 (9): 1067-72, 2001.
- 12- DASANI B.M., SIGAL S.H. and LIEBER C.S.: Analysis of risk factors for chronic hepatic encephalopathy: The role of *Helicobacter pylori* infection. *Am. J. Gastroenterol.*, 93 (5): 726-31, 1998.
- 13- ABDEL-HADY H., ZAKI A., BADRA G., LOTFY M., SELMI C., GIORGINI A., EL-SAYED M. and BADR

- R.: Helicobacter pylori infection in hepatic encephalopathy: Relationship to plasma endotoxins and blood ammonia. Hepatol. Res. Off J. Jpn. Soc. Hepatol., 3 (12): 1026-33, 2007.
- 14- GISBERT J.P.: Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol. Res. Pract, 2012.
- 15- GOPAL R., ELAMURUGAN T.P., KATE V., JAGDISH S. and BASU D.: Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. World J. Gastrointest Pharmacol. Ther., 4 (2): 23-7, 2013
- 16- CHENG H., HU F., ZHANG G., SHI R., DU Y., LI Z., HAN W., LI Y., WU Q. and QIAN K.: Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: A multi-central, randomized, controlled clinical study. Abstract, Europe PMC, 90 (2):79-82, 2010.
- 17- VÁSCONEZ C., ELIZALDE J.I., LLACH J., GINÈS A., DE LA ROSA C., FERNÁNDEZ R.M., MAS A., SANTAMARÍA J., BORDAS J.M., PIQUÉ J.M. and TERÉS J.: Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: Effects of eradication. J. Hepatol., 30 (2): 260-264, 1999.
- 18- MIQUEL J., BARCENA R., BOIXEDA D., FERNÁNDEZ J., SANROMAN A.L., MARTÍN-DE-ARGILA C. and RAMOSA F.: Role of Helicobacter pylori infection and its eradication in patients with subclinical hepatic encephalopathy. Eur. J. Gastroenterol. Hepatol., 13 (9): 1067-7, 2001.
- 19- AGRAWAL A., GUPTA A., CHANDRA M. and KOOWAR S.: Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication. Indian J. Gastroenterol., 30 (1): 29-32, 2011.

## تأثير اعادة هيليكوباكتر بيلورى على اعتلال الدماغ الكبدى فى مرضى التليف الكبدى المصريين

خلفية البحث: يتم إنتاج من الأمونيا عن طريق هيليكوباكتر بيلورى H. pylori، ومن خلال القضاء عليها، يمكن تحسين درجة الاعتلال الدماغى الكبدى.

الهدف من البحث: لتقييم تأثير القضاء على هيليكوباكتر بيلورى H. pylori على مرحلة الاعتلال الدماغى الكبدى.

المرضى وطرق البحث: هذه الدراسة شملت ٨٠ مريض تليف الكبد مصابين بالبكتيريا الحلزونية البوابية H. pylori والتي تم تشخيصها عن طريق البراز AG. تم تقسيم المرضى الخاضعين للدراسة إلى مجموعتين أخرى وفقاً لنظام القضاء على هيليكوباكتر بيلورى H. pylori تمت المتابعة بعد شهر واحد لتقييم أثر ابادتها على مرحلة اعتلال الدماغ الكبدى.

النتائج: المتابعة بعد شهر واحد من العلاج، أظهرت معدل علاج هيليكوباكتر بيلورى H. pylori فعالية أعلى مع العلاج القائم على الليفوفلوكساسين (٨٩.٤٧٪) مقارنة بنظام الكلاريثروميسين (٧٦.٤٧٪) مع قيمة  $p=0.3$  تحسن معظم مرضى التليف الكبدى المصابين بالاعتلال الدماغى الكبدى بعد العلاج الناجح ولكن بدون دلالة إحصائية.